Association of plasma angiogenin with risk of major cardiovascular events in type 2 diabetes
Authors' conclusion
Plasma angiogenin was associated with the risk of future cardiovascular events in patients with T2D and may be a promising novel biomarker for identifying high-risk T2D patients for early management.
Study context
- Population
- Patients with T2D recruited from a secondary hospital and a primary care facility
- Participants
- 1,083 patients
- Exposure
- Plasma angiogenin and MACE risk
- Outcome
- Four-point MACE: nonfatal MI, stroke, unstable angina pectoris leading to hospitalization and cardiovascular death
- Follow-up
- Median 9.3 years
Main finding
As reported in the abstract
MACE per doubling of plasma angiogenin
MACE identified
109
10%
Unadjusted increased risk per doubling
3.10-fold
95% CI 1.84–5.22
aHR per doubling, adjusted for demographic and cardiometabolic risk factors
2.38
95% CI 1.34–4.23
aHR per doubling, additionally adjusted for estimated glomerular filtration rate (eGFR) and urinary albumin to creatinine ratio (uACR)
1.90
95% CI 1.02–3.53
Observational data: associations, not effects.
Further findings
Plasma angiogenin in tertiles
- Consistent outcome when angiogenin analysed as a categorical variable in tertiles
Original publication
Association of plasma angiogenin with risk of major cardiovascular events in type 2 diabetes. Cardiovasc Diabetol. Published 15 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →